Table 1 Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer
Parameters | Number of cases (%) |
|---|---|
Gender | |
Male | 106 (93.0) |
Female | 8 (7.0) |
Age (years) | |
< 62 | 56 (49.1) |
≥ 62 | 58 (50.9) |
Clinical stage | |
I | 38 (33.3) |
II | 16 (14.0) |
III | 28 (24.6) |
IV | 32 (28.1) |
T classification | |
T1& T2 | 59 (51.8) |
T3 | 29 (25.4) |
T4 | 26 (22.8) |
N classification | |
N0 | 86 (75.4) |
N1& N2& N3 | 28 (24.6) |
M classification | |
No | 103 (90.4) |
Yes | 11 (9.6) |
Thyroid cartilage invasion | |
No | 88 (77.2) |
Yes | 26 (22.8) |
Type | |
Supraglottic | 35 (30.7) |
Subglottic | 4 (3.5) |
Glottic | 74 (64.9) |
Transglottic | 1 (0.9) |
Expression of CD44 | |
Low expression | 57 (50.0) |
High expression | 57 (50.0) |
Expression of CD133 | |
Low expression | 62 (54.4) |
High expression | 52 (45.6) |
Relapse status (at follow-up) | |
No | 78 (68.4) |
Yes | 36 (31.6) |
Vital status (at follow-up) | |
Alive | 93 (81.6) |
Dead | 21 (18.4) |
Expression of PLOD2 | |
Low expression | 59 (51.8) |
High expression | 55 (48.2) |